DraftKings earnings preview:DraftKings (DKNG) reports earnings with forecasts on the total U.S. sports betting/iGaming market continuing to be pushed higher as more states report strong engagement. Morgan Stanley thinks sports betting/iGaming revenue could hit $7B in 2021. Look for an important update from DraftKings with its report on the transition of the tech stack to SBTech from Kambi, which Morgan Stanley sees as an important way for the company to grab more market share. EYES ON MASSACHUSETTS SENATE:The Boston Red Sox and DraftKings announced a deal making DraftKings the official Daily Fantasy Sports provider of the franchise. The Red Sox represent DraftKings' most recent local sponsorship agreement in the Northeast, after previously solidifying deals with the New England Patriots and Boston Celtics. While DraftKings has solidified deal with Boston sports teams, there is still no consensus proposal for sports betting in Massachusetts. While both sides reportedly want to work together in more than just DFS, Waters said. there is work to be done before a DraftKings Sportsbook is found at Fenway Park. Allowing teams to place sportsbooks in or near their facilities was suggested by two amendments to the House sports betting proposal. The idea was partially shut down. H 3993 calls for the Massachusetts Gaming Commission to study giving professional teams and leagues betting licenses. The amended bill passed 156-3 in the House last Thursday and was referred to Senate Ways and Means Monday. The Massachusetts Senate has been quiet since the House passed the bill and it is unclear when it will act. The Senate has its own sports betting proposal in S 269 from Senator Eric Lesser. That bill has not been amended since the Joint Committee on Economic Development and Emerging Technologies hearing. The two bills differ on collegiate betting, tax rate, license fees and league data. LSR noted that If the Senate passes S 269, a conference committee could be the most likely outcome to reach a compromise.
VAN YOU SCARED ME WITH GO PRO!!! I WAS AFRAID TO LOOK THAT IT WOULD BE MUCH LOWER. I DID SELL A BUNCH OUT of my E Trade acct a long time ago FOR LACK OF MOVEMENT Ideas For Now- ADDING GO- PRO TO THE IDEAS FOR NOW PORTFOLIO! @$9.00 GPRO And you're killing the stk i figured it was at $4 It's $9.92. Why all the hate speech, it's dead it's not the worst stock in the world. Shheze you gave me a heart attack! My kid's acct still has some! THEY REPORT TOMORROW SHOULD I GET OUT!!!!! >WEIS (Horse faced Guy) IN ON GXO!!!! Up another $7<---
Leslies beat. 28K shares on the offer at $24.30 though. No takers. It got as high as $25 though. Lemonade is getting hammered, -10% The good news: Granite Awarded $64 Million Road Separation Contract in Southern California August 04, 2021 05:30 PM Eastern Daylight Time WATSONVILLE, Calif.--(BUSINESS WIRE)--Granite (NYSE:GVA) has been awarded a $64 million contract for the Jurupa Road Grade Separation project by the Riverside County Transportation Department in Jurupa Valley, California. The contract award was included in Granite’s second quarter committed and awarded projects (CAP).
Hey lets watch this--> Jounce Therapeutics EPS beats by $0.28, beats on revenue Aug. 05, 2021 7:10 AM ETJounce Therapeutics, Inc. (JNCE)Jounce Therapeutics, Inc. (JNCE) Jounce Therapeutics(NASDAQ:JNCE): Q2 GAAP EPS of -$0.08 beats by $0.28. Revenue of $25.4M beats by $17.24M. As of June 30, 2021, cash, cash equivalents and investments were $246.1 million, compared to $213.2 million as of December 31, 2020. For a Bio that's a big beat, estimates for a bio-- lots of cash in the bank. I don't know the story (yet) feels like it could be a gummy. JNCE-
Regeneron/Sanofi stops late-stage Libtayo study early after improvement in survival in NSCLC patients Aug. 05, 2021 6:23 AM ETRegeneron Pharmaceuticals, Inc. (REGN),SNYRegeneron Pharmaceuticals, Inc. (REGN)Sanofi (SNY) Regeneron Pharmaceuticals(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)announces the Phase 3 trial of PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy wasstopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell lung cancer (NSCLC). In this top-line initial analysis of 466 patients, the combination reduced the risk of death by 29% compared to chemotherapy alone (hazard ratio: 0.71; 95% confidence interval [CI]: 0.53-0.93; p=0.014). Median OS was 22 months for Libtayo and chemotherapy, and 13 months for chemotherapy alone.
Popular grill maker Weber is said to price IPO below range, sells fewer shares-? Roku CEO: COVID reopening led to lower TV watching last quarter- What does that mean for gaming? & gambling? GoDaddy stock dips after profit miss, soft sales forecast- This could be an opportunity to get back in. Boot Barn EPS beats by $0.45, beats on revenue-- Boots for the un vaccinated! Leslie’s EPS beats by $0.08, beats on revenue-!!!!!!! Aug. 04, 2021 4:51 PM ETLeslie's, Inc. (LESL)Leslie's, Inc. (LESL) Leslie’s(NASDAQ:LESL): Q3 Non-GAAP EPS of $0.64 beats by $0.08; GAAP EPS of $0.61 beats by $0.08. Revenue of $596.5M beats by $24.69M.... Nothing wrong with that report is there? Yet no stock movement which makes me glad I did not waste my time here and makes me wonder more about DKNG... That one is close enough to a Meme stk to get some REAL movement... I think it could move $10....
We have yet to add one of these " rental " plays to the Phantasma Rent-A-Center EPS beats by $0.27, beats on revenue Aug. 04, 2021 4:47 PM ETRent-A-Center, Inc. (RCII) Rent-A-Center(NASDAQ:RCII): Q2 Non-GAAP EPS of $1.63beats by $0.27; GAAP EPS of $0.90misses by $0.44. Revenue of $1.16B (+75.4% Y/Y)beats by $30M.